# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Jonathan Chappell maintains Frontline (NYSE:FRO) with a Outperform and lowers the price target fr...
Jefferies analyst Omar Nokta maintains Frontline (NYSE:FRO) with a Buy and maintains $30 price target.
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Jefferies analyst Omar Nokta upgrades Frontline (NYSE:FRO) from Hold to Buy and raises the price target from $22 to $30.
JP Morgan analyst Samuel Bland maintains Frontline (NYSE:FRO) with a Neutral and lowers the price target from $23 to $22.3.
Frontline Plc reported Q4 revenue of $415M, beating consensus of $270.06M. Net income, EPS, and cash flow all decreased compare...